Catalyst Pharmaceuticals (CPRX) Liabilities and Shareholders Equity (2010 - 2026)

Catalyst Pharmaceuticals (CPRX) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 26.27% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $4.3 billion (up 32.0% YoY), and the FY2025 full-year result was $1.1 billion, up 29.66% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $1.1 billion in Q1 2026 and bottomed at $247.0 million in Q1 2022.
• The 5-year median for Liabilities and Shareholders Equity is $646.7 million (2024), against an average of $654.0 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity rose 24.04%; it then soared 86.83% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $375.6 million in 2022, then increased by 25.15% to $470.1 million in 2023, then jumped by 81.11% to $851.4 million in 2024, then advanced by 29.66% to $1.1 billion in 2025, then climbed by 3.95% to $1.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.

Peer Comparison